

Bone-marrow derived stem cell transplantation in patients undergoing left ventricular restoration surgery for dilated ischaemic end-stage heart failure

Submission date 27/07/2009	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 14/10/2009	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 12/04/2017	Condition category Circulatory System	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr Raimondo Ascione

Contact details
Level 7, Research Floor
University of Bristol
Bristol Royal Infirmary
Bristol
United Kingdom
BS2 8HW
-
R.Ascione@bristol.ac.uk

Additional identifiers

Protocol serial number
CS/2008/3027

Study information

Scientific Title

Bone-marrow derived stem cell transplantation in patients undergoing left ventricular restoration surgery for dilated ischaemic end-stage heart failure: a randomised blinded controlled trial

Acronym

TransACT 2

Study objectives

The aim of this study is to determine the effects of CD133+ autologous stem cells transplantation in and around asynergic non-viable left ventricular (LV) segments in patients with dilated ischaemic heart disease undergoing left ventricular reshaping surgery and coronary artery bypass graft (CABG).

Ethics approval required

Old ethics approval format

Ethics approval(s)

NHS Southmead Research Ethics Committee, 20/07/2005, ref: 05/K2002/49

Study design

Double-blind randomised placebo-controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Cardiac disease/coronary surgery

Interventions

Eligible patients undergoing SVR surgery will be allocated to either:

1. Intervention group: SVR surgery and transplantation of autologous CD133+
2. Control group: SVR surgery and injection of placebo, i.e. autologous plasma

Please use following contact details to request a patient information sheet:

Dr Jodi Taylor

Clinical Trials Co-ordinator

Bristol Heart Institute

University of Bristol

Level 7, Bristol Royal Infirmary

Bristol, BS2 8HW

United Kingdom

Tel: +44 (0)117 342 3398

Email: j.taylor@bristol.ac.uk

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Regional LV thickening of the 'affected' segments 6 months after surgery, i.e. end systolic thickness minus end diastolic thickness (millimetres). Affected segments will be those scored on the cardiac MRI taken 3 - 5 days after surgery, as 1 - 5 (dysfunctional) on a 5-point scale. Affected segments will be the segments which the surgeons aims to inject with stem cells or plasma. Measured at baseline (3 - 5 days post-operatively) and 6 months follow-up.

Key secondary outcome(s)

1. Mid-term generic and cardiac-specific health status and quality of life, measured at baseline and 6 months follow-up
2. End systolic volume and stroke volume quantified by cardiac MRI, measured at baseline (3 - 5 days post-operatively) and 6 months follow-up
3. Myocardial injury throughout the duration of the study by measuring troponin I levels (24 hours pre-operatively, surgery, 4, 12, 24 hours post-operatively, 6 weeks and 6 months follow-up)

Completion date

01/02/2012

Eligibility

Key inclusion criteria

1. Previous anterior myocardial infarction (with evidence of large surgically excludible scar at cardiac magnetic resonance imaging [MRI])
2. Significant LV dilation (left ventricular end-systolic volume index [LVESVI] greater than or equal to 60 ml/m²)
3. Left ventricular ejection fraction less than or equal to 35%
4. New York Heart Association (NYHA) class III/IV and one episode of congestive heart failure (CHF) requiring medical attention
5. Elective left ventricular restoration surgery indicated
6. Elective CABG indicated to bypass stenoses or occlusions of coronary arteries
7. Patient aged 16 years or over and under 80 years old, either sex

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Severe acute renal failure requiring dialysis or serum creatinine greater than or equal to 200 mmol/L

2. Atrial fibrillation
3. Malignancy
4. Debilitating neurological disease
5. Emergency operation for unstable angina
6. Previous cardiac surgery/sternotomy
7. Concomitant valve procedures
8. History of significant ventricular arrhythmias
9. History of pacemaker and/or defibrillator insertion
10. Right ventricular (RV) failure
11. Pulmonary hypertension greater than 60 mmHg (angiogram or Elixis)
12. Known active infection
13. Chronic inflammatory disease
14. Contraindication for bone marrow aspiration
15. Female subjects of childbearing potential

Date of first enrolment

01/08/2009

Date of final enrolment

01/02/2012

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Level 7, Research Floor

Bristol

United Kingdom

BS2 8HW

Sponsor information

Organisation

University Hospitals Bristol NHS Foundation Trust (UK)

ROR

<https://ror.org/04nm1cv11>

Funder(s)

Funder type
Government

Funder Name
National Institute for Health Research (NIHR) (UK) - Biomedical Research Unit

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration